Targeting a specific protein to prevent leukemia relapse and complications after stem cell transplants
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation
This study is looking at a new way to help patients with leukemia who are getting a stem cell transplant by using special T cells that target a protein called CD83, which could help prevent the cancer from coming back and reduce side effects from the transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10812513 on NIH RePORTER |
What this research studies
This research focuses on improving outcomes for patients undergoing allogeneic hematopoietic cell transplantation by targeting CD83, a protein involved in immune responses. The approach involves using engineered T cells that specifically attack leukemia cells expressing CD83 while minimizing damage to healthy cells. By doing so, the research aims to reduce the risk of both leukemia relapse and graft-versus-host disease (GVHD), a common complication after transplantation. The study will assess the effectiveness of these CD83-targeted T cells in preventing disease recurrence and improving patient survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with acute leukemia who are scheduled to undergo allogeneic hematopoietic cell transplantation.
Not a fit: Patients who do not have acute leukemia or those who are not candidates for stem cell transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance the survival rates and quality of life for patients undergoing stem cell transplants by reducing the chances of leukemia returning and minimizing harmful side effects.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies in reducing complications and improving outcomes in leukemia treatment, indicating potential for success in this novel approach.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Betts, Brian C — Roswell Park Cancer Institute Corp
- Study coordinator: Betts, Brian C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.